Abstract:Objective The occurrence of multidrug resistance (MDR) is a major cause of resistance to chemotherapeutic agents in patients with lung cancer, in part owing to the overexpression of MDR-related proteins. Technetium-99m-hexakis-2-methoxyisobutylisonitrile ( 99m Tc-MIBI) has been shown to be a substrate for some MDR-related proteins. The aim of this study is to evaluate the role of 99m Tc-MIBI scintigraphy for functional imaging of MDR-related protein phenotypes. Methods To determine the correlation between 99m Tc-MIBI scintigraphy and the expression level of P-glycoprotein (Pgp), multidrug-resistance protein (MRP), and glutathione- S -transferase Pi (GSTπ), 26 patients (17 men and 9 women, median age 57.5 years) with primary lung cancer were investigated. Following intravenous administration of 925 MBq 99m Tc-MIBI, single-photon emission computed tomography (SPECT) and computed tomography (CT) were performed at 15 min and 2 h. On the basis of the fused images, tumor to background (T/B) ratio of both early and delayed images, and washout rate (WR%) of 99m Tc-MIBI were calculated. The immunohistochemical staining of Pgp, MRP, and GSTπ was performed, and the expression level was semiquantitated using a pathoimage analysis system. The imaging results were compared with the status of Pgp, MRP, and GSTπ expression. Results The WR% of 99m Tc-MIBI showed a significant positive correlation with Pgp expression ( r = 0.560, P = 0.003), as no correlation was observed between WR% and MRP or GSTπ ( r = 0.354, P = 0.076; r = 0.324, P = 0.106). Neither early T/B nor delayed T/B correlated with the expression level of Pgp, MRP, and GSTπ. WR%, Pgp, and GSTπ expression showed significant differences between squamous cell carcinoma (group A) and adenocarcinoma (group B). There was no significant difference among Pgp, MRP, and GSTπ expression levels in any cases ( P > 0.05). Conclusions Our data confirmed that 99m Tc-MIBI scintigraphy is useful for determining the MDR caused by Pgp in patients with primary lung cancer.

Expression and Clinical Significance of Multidrug Resistance Proteins in Brain Tumors

Expression of P-glycoprotein/caveolin-1 in blood-brain barrier

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Expression And Significance Of Glucose Transporter-1, P-Glycoprotein, Multidrug Resistance-Associated Protein And Glutathione S-Transferase-Pi In Laryngeal Carcinoma

The Expression of Drug-resistance Genes in Human Gliomas

Research and Clinical Significance of Relevant Signal Transduction Pathways Involved in P-glycoprotein-mediated Multidrug Resistance

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System

A Novel Classifier Combining G Protein-Coupled Receptors and the Tumor Microenvironment is Associated with Survival Status in Glioblastoma.

Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells.

Expressions and clinical significance of varied membrae transport proteins in patients with early non-small cell lung cancer

Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM)

Multidrug Resistance Protein and Topoisomerase 2 Alpha Expression in Non-Small Cell Lung Cancer Are Related with Brain Metastasis Postoperatively.

Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer

[CD147 and Matrix Metallo-Proteinase (MMP) 2 and MMP9 Expression in Multidrug Resistant Breast Cancer Cells Treated with P-glycoprotein Substrate Drugs].

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel

Multidrug resistance-associated proteins and implications in drug development

Modulation of blood-tumor barrier transcriptional programs improves intra-tumoral drug delivery and potentiates chemotherapy in GBM